Glutamine deprivation induces ferroptosis in pancreatic cancer cells

Ferroptosis is a type of programmed cell death closely related to amino acid metabolism. Pancreatic Cancer cells have a strong dependence on glutamine, which serves as a carbon and nitrogen substrate to sustain rapid growth. Glutamine also aids in self-protection mechanisms. However, the effect of glutamine on Ferroptosis in pancreatic Cancer remains largely unknown. Here, we aim to explore the association between Ferroptosis and glutamine deprivation in pancreatic Cancer. The growth of pancreatic Cancer cells in culture media with or without glutamine is evaluated using Cell Counting Kit-8. Reactive Oxygen Species (ROS) are measured by 2',7'-dichlorodihydrofluorescein diacetate staining. Ferroptosis is assessed by BODIPY-C11 dye using confocal microscopy and flow cytometry. Amino acid concentrations are measured using ultrahigh-performance liquid chromatography-tandem mass spectrometry. Isotope-labelled metabolic flux analysis is performed to track the metabolic flow of glutamine. Additionally, RNA sequencing is performed to analyse the genetic alterations. Glutamine deprivation inhibits pancreatic Cancer growth and induces Ferroptosis both in vitro and in vivo. Additionally, glutamine decreases ROS formation via glutathione production in pancreatic Cancer cells. Interestingly, glutamine inhibitors (diazooxonorleucine and azaserine) promotes ROS formation and Ferroptosis in pancreatic Cancer cells. Furthermore, ferrostatin, a Ferroptosis inhibitor, rescues Ferroptosis in pancreatic Cancer cells. Glutamine deprivation leads to changes in molecular pathways, including cytokine-cytokine receptor interaction pathways ( CCL5, CCR4, LTA, CXCR4, IL-6R, and IL-7R). Thus, exogenous glutamine is required for the detoxification of ROS in pancreatic Cancer cells, thereby preventing Ferroptosis.

ferroptosis; glutamine; glutathione; pancreatic cancer; reactive oxygen species.